Study participants had a Pulmonary Scoring Index (PSI) score between 4 and 6 at presentation, reported ≥3 past coughing/wheezing episodes, and were responsive to bronchodilators. PSI score was assessed at baseline and 4 hours after treatment administration.

The reduction in PSI scores was comparable between children treated with montelukast vs placebo (3.08±0.781 vs 2.71±0.825, respectively; P =.167), indicating a lack of benefit of montelukast as an adjuvant to standard therapy for acute moderate asthma.


Venugopal S, Mohan G, Cherungonath A. Effect of addition of single dose of oral montelukast to standard therapy in acute moderate asthma in children 5 to 12 years of age: a randomized double-blind placebo controlled trial. Presented at: CHEST Annual Meeting 2019; October 19-23, 2019; New Orleans, LA. Abstract 1603.